Peter Pitts on communicating with FDA
This article was originally published in The Gray Sheet
Former Associate Commissioner for External Relations will address AdvaMed Medical Technology Communications Conference Oct. 13 in his current role as senior VP-health affairs at New York PR firm Manning, Salvage & Lee. Pitts' luncheon speech will cover the "boundaries of company communications versus FDA communications, best ways to bridge communications gaps with the agency and its use of the Web to promote company advisories," according to an 1agenda for the two-day Washington, D.C. meeting...
You may also be interested in...
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.
Manufacturers warned to keep better electronic records and not falsify data in recent warning letters, ICH adds three residual solvent limits for pharmaceuticals, and the Polish authority hits firm for GMP noncompliance.